Meeting
2023 ASCO Annual Meeting
Prognostic role of TP53 variants in the phase III study of FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone in first-line therapy of RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients (ERMES study).
Authors
Nicola Normanno
Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori-IRCCS Fondazione Pascale, Napoli, Italy
Nicola Normanno , Armando Orlandi , Evaristo Maiello , Anna Maria Rachiglio , Giuseppe Maglietta , Angela Damato , Maria Alessandra Calegari , Lorenzo Antonuzzo , Roberto Bordonaro , Maria Giulia Zampino , Stefano Tamberi , Sara Lonardi , Giuseppe Tonini , Gerardo Rosati , Tiziana Pia Latiano , Emiliano Tamburini , Monica Rosaria Maiello , Marianeve Carotenuto , Carlo Barone , Carmine Pinto
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Epidemiology/Outcomes
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 3544)
DOI
10.1200/JCO.2023.41.16_suppl.3544
Abstract #
3544
Poster Bd #
244
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Impact of primary tumor side on outcomes of every-2-weeks (q2w) cetuximab + first-line FOLFOX or FOLFIRI in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 2 APEC trial.
First Author: Timothy Jay Price
Poster
2015 Gastrointestinal Cancers Symposium
Final analysis of the phase 2 APEC study: Overall survival (OS) data and biomarker subanalyses for first-line FOLFOX or FOLFIRI with cetuximab (cet) once every 2 weeks in patients (pts) with KRAS or RAS (KRAS and NRAS, exons 2-4) wild-type (wt) metastatic colorectal cancer (mCRC).
First Author: Ann-Lii Cheng
Poster
2014 Gastrointestinal Cancers Symposium
FOLFOX4 plus cetuximab administered weekly or every two weeks in first-line treatment of patients with KRAS and NRAS wild-type (wt) metastatic colorectal cancer (mCRC).
First Author: Thomas Brodowicz
Poster
2013 ASCO Annual Meeting
Analysis of KRAS/NRAS and BRAF mutations in the phase III PRIME study of panitumumab (pmab) plus FOLFOX versus FOLFOX as first-line treatment (tx) for metastatic colorectal cancer (mCRC).
First Author: Kelly S. Oliner